Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

K. N Siva Subramanian, Leonard E. Weisman, Torunn Rhodes, Ronald Ariagno, Pablo J. Sánchez, Jean Steichen, Laurence B. Givner, Terese L. Jennings, Franklin H. Top, David Carlin, Edward Connor

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493 (palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication. Objective. To describe the safety, tolerance, immunogenicity and pharmacokinetics of repeat intravenous doses of MEDI-493 in premature infants or infants with bronchopulmonary dysplasia. Design. Phase I/II multicenter, randomized, double blind, placebo-controlled, dose escalation trial. Patient population. Infants born prematurely (≤35 weeks of gestation) who were ≤6 months of age and infants with bronchopulmonary dysplasia who were ≤24 months of age were eligible for study participation. Study agents. Participants received 3, 10 or 15 mg/kg MEDI-493 or 0.9% saline intravenously every 30 days for up to five doses. Results. MEDI-493 was safe and well-tolerated and did not induce a specific anti-MEDI-493 response. The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations. Mean trough serum concentrations 30 days after infusion 1 were 6.8, 36.1 and 60.6 μg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively. After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 μg/ml. After subsequent doses the mean trough values ranged from 14 to 18 μg/ml in those given 3 mg/kg and were >40 μg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 μg/ml and 88 to 96 μg/ml, respectively). Conclusions. MEDI-493 was safe and well-tolerated in this high risk pediatric population. Mean serum concentrations of MEDI-493 that have been shown to produce a 2-log reduction in pulmonary RSV titer in cotton rats were maintained when 10 or 15 mg/kg MEDI-493 was given every 30 days to pediatric patients at high risk for serious RSV disease. Monthly doses of 15 mg/kg maintained concentrations of >40 μg/ml for the majority of patients.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalPediatric Infectious Disease Journal
Volume17
Issue number2
DOIs
StatePublished - Feb 1998

Fingerprint

Antibodies, Monoclonal, Humanized
Bronchopulmonary Dysplasia
Respiratory Syncytial Viruses
Premature Infants
Pharmacokinetics
Safety
Palivizumab
Sigmodontinae
Pediatrics
Lung
Virus Diseases
Virus Replication
Viral Load
Serum
Respiratory Tract Infections
Population
Half-Life
Animal Models
Immunoglobulin G
Placebos

Keywords

  • MEDI-493
  • Monoclonal antibody
  • Palivizumab
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. / Subramanian, K. N Siva; Weisman, Leonard E.; Rhodes, Torunn; Ariagno, Ronald; Sánchez, Pablo J.; Steichen, Jean; Givner, Laurence B.; Jennings, Terese L.; Top, Franklin H.; Carlin, David; Connor, Edward.

In: Pediatric Infectious Disease Journal, Vol. 17, No. 2, 02.1998, p. 110-115.

Research output: Contribution to journalArticle

Subramanian, KNS, Weisman, LE, Rhodes, T, Ariagno, R, Sánchez, PJ, Steichen, J, Givner, LB, Jennings, TL, Top, FH, Carlin, D & Connor, E 1998, 'Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia', Pediatric Infectious Disease Journal, vol. 17, no. 2, pp. 110-115. https://doi.org/10.1097/00006454-199802000-00006
Subramanian, K. N Siva ; Weisman, Leonard E. ; Rhodes, Torunn ; Ariagno, Ronald ; Sánchez, Pablo J. ; Steichen, Jean ; Givner, Laurence B. ; Jennings, Terese L. ; Top, Franklin H. ; Carlin, David ; Connor, Edward. / Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. In: Pediatric Infectious Disease Journal. 1998 ; Vol. 17, No. 2. pp. 110-115.
@article{cac8cf47149244ae9a763897baa57e95,
title = "Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia",
abstract = "Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493 (palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication. Objective. To describe the safety, tolerance, immunogenicity and pharmacokinetics of repeat intravenous doses of MEDI-493 in premature infants or infants with bronchopulmonary dysplasia. Design. Phase I/II multicenter, randomized, double blind, placebo-controlled, dose escalation trial. Patient population. Infants born prematurely (≤35 weeks of gestation) who were ≤6 months of age and infants with bronchopulmonary dysplasia who were ≤24 months of age were eligible for study participation. Study agents. Participants received 3, 10 or 15 mg/kg MEDI-493 or 0.9{\%} saline intravenously every 30 days for up to five doses. Results. MEDI-493 was safe and well-tolerated and did not induce a specific anti-MEDI-493 response. The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations. Mean trough serum concentrations 30 days after infusion 1 were 6.8, 36.1 and 60.6 μg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively. After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 μg/ml. After subsequent doses the mean trough values ranged from 14 to 18 μg/ml in those given 3 mg/kg and were >40 μg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 μg/ml and 88 to 96 μg/ml, respectively). Conclusions. MEDI-493 was safe and well-tolerated in this high risk pediatric population. Mean serum concentrations of MEDI-493 that have been shown to produce a 2-log reduction in pulmonary RSV titer in cotton rats were maintained when 10 or 15 mg/kg MEDI-493 was given every 30 days to pediatric patients at high risk for serious RSV disease. Monthly doses of 15 mg/kg maintained concentrations of >40 μg/ml for the majority of patients.",
keywords = "MEDI-493, Monoclonal antibody, Palivizumab, Respiratory syncytial virus",
author = "Subramanian, {K. N Siva} and Weisman, {Leonard E.} and Torunn Rhodes and Ronald Ariagno and S{\'a}nchez, {Pablo J.} and Jean Steichen and Givner, {Laurence B.} and Jennings, {Terese L.} and Top, {Franklin H.} and David Carlin and Edward Connor",
year = "1998",
month = "2",
doi = "10.1097/00006454-199802000-00006",
language = "English (US)",
volume = "17",
pages = "110--115",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

AU - Subramanian, K. N Siva

AU - Weisman, Leonard E.

AU - Rhodes, Torunn

AU - Ariagno, Ronald

AU - Sánchez, Pablo J.

AU - Steichen, Jean

AU - Givner, Laurence B.

AU - Jennings, Terese L.

AU - Top, Franklin H.

AU - Carlin, David

AU - Connor, Edward

PY - 1998/2

Y1 - 1998/2

N2 - Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493 (palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication. Objective. To describe the safety, tolerance, immunogenicity and pharmacokinetics of repeat intravenous doses of MEDI-493 in premature infants or infants with bronchopulmonary dysplasia. Design. Phase I/II multicenter, randomized, double blind, placebo-controlled, dose escalation trial. Patient population. Infants born prematurely (≤35 weeks of gestation) who were ≤6 months of age and infants with bronchopulmonary dysplasia who were ≤24 months of age were eligible for study participation. Study agents. Participants received 3, 10 or 15 mg/kg MEDI-493 or 0.9% saline intravenously every 30 days for up to five doses. Results. MEDI-493 was safe and well-tolerated and did not induce a specific anti-MEDI-493 response. The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations. Mean trough serum concentrations 30 days after infusion 1 were 6.8, 36.1 and 60.6 μg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively. After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 μg/ml. After subsequent doses the mean trough values ranged from 14 to 18 μg/ml in those given 3 mg/kg and were >40 μg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 μg/ml and 88 to 96 μg/ml, respectively). Conclusions. MEDI-493 was safe and well-tolerated in this high risk pediatric population. Mean serum concentrations of MEDI-493 that have been shown to produce a 2-log reduction in pulmonary RSV titer in cotton rats were maintained when 10 or 15 mg/kg MEDI-493 was given every 30 days to pediatric patients at high risk for serious RSV disease. Monthly doses of 15 mg/kg maintained concentrations of >40 μg/ml for the majority of patients.

AB - Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants. MEDI-493 (palivizumab) is a humanized monoclonal antibody to the fusion protein of RSV and is active in animal models for prevention of pulmonary RSV replication. Objective. To describe the safety, tolerance, immunogenicity and pharmacokinetics of repeat intravenous doses of MEDI-493 in premature infants or infants with bronchopulmonary dysplasia. Design. Phase I/II multicenter, randomized, double blind, placebo-controlled, dose escalation trial. Patient population. Infants born prematurely (≤35 weeks of gestation) who were ≤6 months of age and infants with bronchopulmonary dysplasia who were ≤24 months of age were eligible for study participation. Study agents. Participants received 3, 10 or 15 mg/kg MEDI-493 or 0.9% saline intravenously every 30 days for up to five doses. Results. MEDI-493 was safe and well-tolerated and did not induce a specific anti-MEDI-493 response. The mean half-life of 20 days was comparable with that of other immunoglobulin G preparations. Mean trough serum concentrations 30 days after infusion 1 were 6.8, 36.1 and 60.6 μg/ml for the 3-, 10- and 15-mg/kg dose groups, respectively. After Infusion 2 the trough concentrations were 11.9, 45.2 and 70.7 μg/ml. After subsequent doses the mean trough values ranged from 14 to 18 μg/ml in those given 3 mg/kg and were >40 μg/ml for patients who received 10 or 15 mg/kg MEDI-493 (46 to 72 μg/ml and 88 to 96 μg/ml, respectively). Conclusions. MEDI-493 was safe and well-tolerated in this high risk pediatric population. Mean serum concentrations of MEDI-493 that have been shown to produce a 2-log reduction in pulmonary RSV titer in cotton rats were maintained when 10 or 15 mg/kg MEDI-493 was given every 30 days to pediatric patients at high risk for serious RSV disease. Monthly doses of 15 mg/kg maintained concentrations of >40 μg/ml for the majority of patients.

KW - MEDI-493

KW - Monoclonal antibody

KW - Palivizumab

KW - Respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=6844242330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844242330&partnerID=8YFLogxK

U2 - 10.1097/00006454-199802000-00006

DO - 10.1097/00006454-199802000-00006

M3 - Article

C2 - 9493805

AN - SCOPUS:6844242330

VL - 17

SP - 110

EP - 115

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 2

ER -